T Cell Vaccinology: Beyond the Reflection of Infectious Responses

Trends in Immunology

Volumn 37, Issue 3, 2016, Pages 170-180

  Pennock, Nathan D ^a   Kedl, Justin D ^b   Kedl, Ross M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; INTERLEUKIN 27; SUBUNIT VACCINE; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN SPECIFICITY; APOPTOSIS; B LYMPHOCYTE; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; HUMAN; INFECTION; NONHUMAN; REVIEW; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD8+ T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFECTION; LYMPHOCYTE ACTIVATION; RECEPTORS, TUMOR NECROSIS FACTOR; VACCINES, SUBUNIT;

EID: 84959275681     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.01.001     Document Type: Review

References (99)

1. Starbeck-Miller G.R., Harty J.T. The role of Il-12 and type I interferon in governing the magnitude of CD8 T cell responses. Adv. Exp. Med. Biol. 2015, 850:31-41.
2. Pennock N.D., et al. IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:16472-16477.
3. Hunter C.A., Kastelein R. Interleukin-27: balancing protective and pathological immunity. Immunity 2012, 37:960-969.
4. + cells in nonhealing Leishmania major infection. J. Immunol. 2009, 183:4619-4627.
5. Hendriks J., et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 2000, 1:433-440.
6. + T cell responses by pathogens typically depends on CD70-mediated interactions with dendritic cells. Eur. J. Immunol. 2007, 37:716-728.
7. + T cell responses of low antigen affinity to protect against viral variants. Immunity 2011, 35:97-108.
8. + T cells. Immunity 2014, 41:127-140.
9. + T cells. J. Immunol. 2005, 174:710-717.
10. McWilliams J.A., et al. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine 2010, 28:1468-1476.
11. + cytotoxic T cell responses in vivo. J. Immunol. 2004, 172:6039-6046.
12. Sanchez P.J., Kedl R.M. An alternative signal 3: CD8ζ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling. Vaccine 2012, 30:1154-1161.
13. Sanchez P.J., et al. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 2007, 178:1564-1572.
14. + T cell response after protein immunization. J. Immunol. 2008, 181:1071-1082.
15. + T cells after peptide immunization. Eur. J. Immunol. 2013, 43:3314-3323.
16. Glenny A.T. The principles of immunity applied to protective inoculation against diphtheria. J. Hyg. 1925, 24:301-320.
17. Glenny A.T. Insoluble precipitates in diphtheria and tetanus immunization. Br. Med. J. 1930, 2:244-245.
18. Glenny A., Tand Barr M. The precipitation of diphtheria toxoid by potash alum. J. Pathol. Bacteriol. 1931, 34:131-138.
19. Coffman R.L., et al. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
20. + T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. 2010, 207:223-235.
21. Poltorak A., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
22. Vasilakos J.P., et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol. 2000, 204:64-74.
23. Oh J.Z., Kedl R.M. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 2010, 185:4602-4608.
24. Cerutti A., et al. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat. Rev. Immunol. 2013, 13:118-132.
25. Pape K.A., et al. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011, 331:1203-1207.
26. Taylor J.J., et al. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J. Exp. Med. 2012, 209:597-606.
27. + T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion. J. Exp. Med. 2009, 206:435-448.
28. + T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008, 28:859-869.
29. Schmidt N.W., et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14017-14022.
30. Gattinoni L., et al. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6:383-393.
31. Rosenberg S.A., et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 2003, 26:385-393.
32. Dudley M.E., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 2001, 24:363-373.
33. Rosenberg S.A., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4:321-327.
34. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16168-16173.
35. Dudley M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
36. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
37. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009, 21:233-240.
38. + T cells. Nature 2012, 486:545-548.
39. + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17469-17474.
40. Murali-Krishna K., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8:177-187.
41. + T cells in primary and secondary influenza pneumonia. Immunity 1998, 8:683-691.
42. Harty J.T., et al. Primary and secondary immune responses to Listeria monocytogenes. Curr. Opin. Immunol. 1996, 8:526-530.
43. + T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 2005, 201:95-104.
44. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 2004, 199:775-784.
45. + T cell responses. J. Immunol. 2010, 185:2106-2115.
46. Assudani D., et al. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res. 2008, 68:9892-9899.
47. Hailemichael Y., et al. Persistent antigen at vaccination sites induces tumor-specific CD8ζ T cell sequestration, dysfunction and deletion. Nat. Med. 2013, 19:465-472.
48. Bonifaz L.C., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 2004, 199:815-824.
49. Thompson E.A., et al. Human anti-CD40 antibody and poly IC:LC adjuvant combination induces potent T cell responses in the lung of nonhuman primates. J. Immunol. 2015, 195:1015-1024.
50. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 2009, 9:271-285.
51. Nolte M.A., et al. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 2009, 229:216-231.
52. + memory T cells and their capacity for secondary expansion. J. Immunol. 2005, 175:1665-1676.
53. Hendriks J., et al. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J. Exp. Med. 2003, 198:1369-1380.
54. + T cell responses to influenza. Nat. Immunol. 2010, 11:216-224.
55. + T cells. J. Immunol. 2008, 181:5990-6001.
56. Salek-Ardakani S., et al. The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J. Clin. Invest. 2010, 121:296-307.
57. + T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J. Exp. Med. 2007, 204:1095-1106.
58. Taraban V.Y., et al. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 2004, 173:6542-6546.
59. + T cell priming. J. Immunol. 2006, 177:2969-2975.
60. + T cell help. J. Immunol. 2012, 188:3829-3838.
61. Edwards L.E., et al. Phenotype and function of protective, CD4-independent CD8 T cell memory. Immunol. Res. 2013, 55:135-145.
62. Yoshida H., Hunter C.A. The immunobiology of interleukin-27. Annu. Rev. Immunol. 2015, 33:417-443.
63. Amadi-Obi A., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007, 13:711-718.
64. Stumhofer J.S., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 2006, 7:937-945.
65. Findlay E.G., et al. Essential role for IL-27 receptor signaling in prevention of Th1-mediated immunopathology during malaria infection. J. Immunol. 2010, 185:2482-2492.
66. + T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J. Immunol. 2012, 188:1178-1190.
67. Villarino A., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
68. + T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat. Immunol. 2011, 12:327-334.
69. Hunter C.A., et al. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol. Rev. 2004, 202:106-114.
70. Batten M., et al. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J. Immunol. 2008, 180:2752-2756.
71. Morishima N., et al. A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J. Biomed. Biotechnol. 2010, 2010:605483.
72. Shinozaki Y., et al. Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int. J. Cancer 2009, 124:1372-1378.
73. Curtsinger J., Mand Mescher M.F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 2010, 22:333-340.
74. Aichele P., et al. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 2006, 176:4525-4529.
75. Curtsinger J.M., et al. CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J. Immunol. 2003, 171:5165-5171.
76. Pearce E., Land Shen H. Generation of CD8 T cell memory is regulated by IL-12. J. Immunol. 2007, 179:2074-2081.
77. Xiao Z., et al. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J. Immunol. 2009, 182:2786-2794.
78. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 2004, 199:227-250.
79. + T cells. J. Immunol. 2003, 170:1822-1829.
80. + T cells by enhancing T cell receptor signaling. Immunity 2013, 38:140-152.
81. White R.G., et al. Studies on antibody production. III. The alum granuloma. J. Exp. Med. 1955, 102:73-82.
82. Holt L.B. Quantitative studies in diphtheria prophylaxis; the primary response. Br. J. Exp. Pathol. 1949, 30:289-297.
83. + T cell sequestration, dysfunction and deletion. Nat. Med. 2013, 19:465-472.
84. Reinhardt R.L., et al. Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation. J. Exp. Med. 2003, 197:751-762.
85. Matos I., et al. Targeting antigens to dendritic cells in vivo induces protective immunity. PLoS ONE 2013, 8:e67453.
86. Oh J.Z., et al. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 2012, 118:3028-3038.
87. Kastenmuller K., et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 2011, 121:1782-1796.
88. Chatterjee B., et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012, 120:2011-2020.
89. + T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 2005, 6:1236-1244.
90. + T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 2009, 31:296-308.
91. Buck M.D., et al. T cell metabolism drives immunity. J. Exp. Med. 2015, 212:1345-1360.
92. Araki K., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
93. + T cell memory development. Immunity 2012, 36:68-78.
94. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
95. Crompton J.G., et al. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol. Rev. 2014, 257:264-276.
96. + T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011, 17:5343-5352.
97. van Elsas A., et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 2001, 194:481-489.
98. Duraiswamy J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73:3591-3603.
99. Soares K.C., et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother. 2015, 38:1-11.